Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT ID: NCT06757634
Last Updated: 2026-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
674 participants
INTERVENTIONAL
2025-07-24
2028-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886
Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)
NCT03829306
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT06638307
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant
Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant
Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
Other Names:
• PF-05212384 Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle.
Other Names:
• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle
Other Names:
• KISQALI® Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant every 2 weeks during Cycle 1 and then every 4 weeks
Other Names:
• Faslodex
Arm B: Palbociclib or Ribociclib + Fulvestrant
Drug: Palbociclib Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle
Other Names:
• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle
Other Names:
• KISQALI®
Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant approximately every 2 weeks during Cycle 1 then approximately every 4
Other Names:
• Faslodex
Arm B: Palbociclib or Ribociclib + Fulvestrant
Drug: Palbociclib Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle
Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant
Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
Other Names:
• PF-05212384 Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle.
Other Names:
• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle
Other Names:
• KISQALI® Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant every 2 weeks during Cycle 1 and then every 4 weeks
Other Names:
• Faslodex
Arm B: Palbociclib or Ribociclib + Fulvestrant
Drug: Palbociclib Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle
Other Names:
• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle
Other Names:
• KISQALI®
Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant approximately every 2 weeks during Cycle 1 then approximately every 4
Other Names:
• Faslodex
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant
Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
Other Names:
• PF-05212384 Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle.
Other Names:
• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle
Other Names:
• KISQALI® Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant every 2 weeks during Cycle 1 and then every 4 weeks
Other Names:
• Faslodex
Arm B: Palbociclib or Ribociclib + Fulvestrant
Drug: Palbociclib Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle
Other Names:
• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle
Other Names:
• KISQALI®
Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant approximately every 2 weeks during Cycle 1 then approximately every 4
Other Names:
• Faslodex
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue for the duration of the study.
3. Negative pregnancy test for females of childbearing potential. Female subjects who are not surgically sterile must use a medically effective contraceptive method from screening until 2 years after the last dose of study treatment.
4. Progression of disease during or within 12 months of completing (neo)adjuvant ET.
5. Adequate archival, fresh tumor tissue, or liquid biopsy for the analysis of PIK3CA mutational status.
6. Permitted prior therapies:
1. (neo)adjuvant fulvestrant or any selective ER degrader only if the treatment duration \< 6 months
2. (neo)adjuvant chemotherapy
3. (neo)adjuvant CDK4/6 inhibitor, unless PD was on or within 6 months of discontinuation of CDK4/6i
7. Subject has radiologically measurable disease according to RECIST v1.1, per local assessment. Patients with evaluable bone-only disease are not eligible. Patients with bone-only disease that has lytic or mixed lytic/blastic lesions and at least one measurable soft tissue component per RECIST v1.1 may be eligible.
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
9. Life expectancy of at least \>6 months.
10. Adequate bone marrow, hepatic, renal and coagulation function.
Exclusion Criteria
2. Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor
3. Prior treatment with systemic anticancer therapy for ABC
4. Subjects with type 1 diabetes
5. Known and untreated, or active, brain or leptomeningeal metastases
6. History of clinically significant cardiovascular abnormalities
7. History of drug-induced symptomatic interstitial lung disease (pneumonitis) or hepatitis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celcuity Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope Medical Center
Duarte, California, United States
Providence Medical Foundation
Fullerton, California, United States
UCLA Hematology Oncology Santa Monica
Los Angeles, California, United States
BRCR Medical Center, Inc- Internal Medicine
Plantation, Florida, United States
BRCR Medical Center, INC
Tamarac, Florida, United States
The University of Kansas Cancer Center
Westwood, Kansas, United States
Mercy Health-Paducah Cancer Center
Paducah, Kentucky, United States
American Oncology Partners, P.A.
Bethesda, Maryland, United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Henry Ford Health System
Detroit, Michigan, United States
Saint Luke's Cancer Institute
Kansas City, Missouri, United States
Washington University School of Medicine in Saint Louis
St Louis, Missouri, United States
SCL Health - Cancer Centers of Montana
Billings, Montana, United States
Weill Cornell Medical College - NewYork-Presbyterian Hospital
New York, New York, United States
Clinical Research Alliance, Inc.
Westbury, New York, United States
Stefanie Spielman Comprehensive Breast Center at Olentangy River Road
Columbus, Ohio, United States
Rittenhouse Hematology/Oncology
Philadelphia, Pennsylvania, United States
Sanford Health
Sioux Falls, South Dakota, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Mays Cancer Center
San Antonio, Texas, United States
Bon Secours St. Francis Medical Oncology Center
Midlothian, Virginia, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Centro de Oncologia e Investigacion Buenos Aires COIBA
Buenos Aires, , Argentina
Pergamino Clinic
Buenos Aires, , Argentina
CENIT Foundation
Buenos Aires, , Argentina
Fleischer Medical Center (Centro Medico Fleischer)
Buenos Aires, , Argentina
Fundacion Respirar
Buenos Aires, , Argentina
Centro Oncológico Korben
Buenos Aires, , Argentina
Alexander Fleming Institute
Buenos Aires, , Argentina
Center for Medical Education and Clinical Research (CEMIC)
Buenos Aires, , Argentina
Cordoba Oncology Institute (IONC)
Córdoba, , Argentina
Centro Oncologico de Excelencia
La Plata, , Argentina
Fundación CORI
La Rioja, , Argentina
Center of Nuclear and Molecular Medicine of Entre Rios (CEMENER)
Paraná, , Argentina
Rosario's Oncology Institute and Medical Specialities (IOR)
Rosario, , Argentina
GenesisCare - St Andrews
Adelaide, , Australia
Breast Cancer Research Centre
Nedlands, , Australia
Icon Cancer Centre Southport
Southport, , Australia
Sydney Adventist Hospital
Wahroonga, , Australia
Westmead Hospital
Westmead, , Australia
The Queen Elizabeth Hospital
Woodville, , Australia
Cliniques Universitaires Saint-Luc
Brussels, , Belgium
Grand Hopital De Charleroi
Charleroi, , Belgium
Universitair Ziekenhuis Gent - Medische Oncologie
Ghent, , Belgium
Jessa Ziekenhuis - Campus Virga Jesse - Medische Oncologie
Hasselt, , Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, , Belgium
CTO Centro de Tratamento Oncológico
Belém, , Brazil
Oncocentro Belo Horizonte
Belo Horizonte, , Brazil
Centro Regional Integrado de Oncologia - CRIO
Fortaleza, , Brazil
Pronutrir Oncologia e Nutrição
Fortaleza, , Brazil
ONCOSITE - Centro de Pesquisa Clinica em Oncologia LTDA
Ijuí, , Brazil
Catarina Pesquisa Clinica
Itajaí, , Brazil
Hospital Sao Lucas da PUCRS
Porto Alegre, , Brazil
Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
Ribeirão Preto, , Brazil
Bahia Oncology Center
Salvador, , Brazil
Hospital A.C.Camargo
São Paulo, , Brazil
Instituto D'or de Pesquisa e Ensino - ONCO STAR
São Paulo, , Brazil
Complex Oncology Center - Burgas
Burgas, , Bulgaria
Multi-profile Hospital For Active Treatment-Uni Hospital Ltd.
Panagyurishte, , Bulgaria
Complex Oncological Centre Ruse
Rousse, , Bulgaria
MHAT Nadezhda - Medical Oncology Clinic
Sofia, , Bulgaria
MHAT "Serdika" EOOD, Base 2 - Second Department of Medical Oncology
Sofia, , Bulgaria
USHAT of Oncology
Sofia, , Bulgaria
Masarykuv onkologicky ustav - Oddeleni klinickych hodnoceni
Brno, , Czechia
Multiscan s.r.o. - Ambulance klinicke onkologie se stacionarem
Hořovice, , Czechia
FN Hradec Kralove - Klinika onkologie a radioterap
Hradec Králové, , Czechia
Fakultni nemocnice Olomouc - Onkologicka klinika
Olomouc, , Czechia
FN Kralovske Vinohrady - Radioterapeuticka a onkologicka klinika
Prague, , Czechia
Fakultni Thomayerova Nemocnice - Onkologicka klinika
Prague, , Czechia
Fakultni Nemocnice v Motole
Prague, , Czechia
Centre Hospitalier Universitaire D'Amiens (Hopital Sud) - Oncologie Medicale - Cancerolo
Amiens, , France
Centre Georges François Baclesse
Caen, , France
Centre Georges Francois Leclerc - service d'oncologie médicale
Dijon, , France
Clinique Victor Hugo / Centre Jean Bernard
Le Mans, , France
CHU La Timone
Marseille, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
Centre Hospitalier Universitaire de Poitiers - Médico-Chirurgical De Cardiol
Poitiers, , France
Centre de Lutte Contre le Cancer (CLCC) - Institut de Cancerologie de l'Ouest (ICO) - Rene Gauducheau - Oncology
Saint-Herblain, , France
Institut Gustave Roussy
Villejuif, , France
Universitätsklinikum Düsseldorf - Gynecology
Düsseldorf, , Germany
Universitätsmedizin Johannes Gutenberg
Mainz, , Germany
CaritasKlinikum Saarbrücken St. Theresia
Saarbrücken, , Germany
Helios Klinikum Wuppertal
Wuppertal, , Germany
Areteio Hospital
Athens, , Greece
University General Hospital of Heraklion
Heraklion, , Greece
Iaso Thessalia General Clinic Private Obstetrics S.A.
Larissa, , Greece
General University Hospital Of Larissa
Larissa, , Greece
Metropolitan Hospital
Piraeus, , Greece
Athens Medical Center S.A.
Thessaloniki, , Greece
Theageneio Cancer Hospital
Thessaloniki, , Greece
Debreceni Egyetem Klinikai Központ Nagyerdei Campus - Onkológiai Klinika
Debrecen, , Hungary
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktatokorhaz
Győr, , Hungary
Békés Megyei Központi Kórház Pándy Kálmán Tagkórház - Oncology
Gyula, , Hungary
Bacs-Kiskun Varmegyei Oktatakorhaz
Kecskemét, , Hungary
University of Pecs- Oncology Dept.
Pécs, , Hungary
Tolna Varmegyei Balassa Janos Korhaz
Szekszárd, , Hungary
Presidio Ospedaliero S. Croce - Oncologia
Fano, , Italy
IRCCS Ospedale Policlinico San Martino - Clinica di Oncologia Medica
Genova, , Italy
IRST IRCCS - Oncologia Medica
Meldola, , Italy
IEO - Istituto Europeo di Oncologia, IRCCS
Milan, , Italy
Istituto Clinico Humanitas
Milan, , Italy
AOU di Modena, Policlinico di Modena - Attività Integrata di Oncologia ed Ematologia
Modena, , Italy
Istituto Nazionale dei Tumori - Fondazione Pascale, IRCCS
Napoli, , Italy
Ospedale Maggiore, AOU Parma
Parma, , Italy
IRCCS Policlinico San Matteo, Università degli studi di Pavia
Pavia, , Italy
Ospedale "Santa Maria delle Croci" di Ravenna - Oncologia
Ravenna, , Italy
Fondazione Policlinico Universitario Campus Bio-Medico
Roma, , Italy
Umberto I Policlinico di Roma, Università La Sapienza
Roma, , Italy
Istituto Clinico Humanitas
Rozzano, , Italy
Azienda Ospedaliera Santa Maria di Terni
Terni, , Italy
Borgo Trento, Ospedale Civile Maggiore, AOU Integrata Verona
Verona, , Italy
Penang Adventist Hospital
George Town, , Malaysia
Hospital Universiti Sains Malaysia
Kota Bharu, , Malaysia
Hospital Kuala Lumpur - Surgery
Kuala Lumpur, , Malaysia
Pantai Hospital Kuala Lumpur
Kuala Lumpur, , Malaysia
Hospital Umum Sarawak
Kuching, , Malaysia
Beacon Hospital
Petaling Jaya, , Malaysia
National Cancer Institute - Radiotherapy and Oncology
Putrajaya, , Malaysia
San Peregrino Unidad de Investigacion
Aguascalientes, , Mexico
Office of Emanuel de la Mora Jimenez, MD/equiv
Guadalajara, , Mexico
Clinical Research Center Chapultepec Mexico City
Mexico City, , Mexico
Centro de Atencion Oncologica Viva
Mexico City, , Mexico
Avix Clinical Research
Monterrey, , Mexico
Filios High Medicine
Monterrey, , Mexico
Administrative Society of Health Services, SC
Morelia, , Mexico
Centrum Onkologii im. prof. F. Lukaszczyka - Ambulatorium Chemioterapii
Bydgoszcz, , Poland
Przychodnia Lekarska KOMED
Konin, , Poland
Pratia MCM Kraków
Krakow, , Poland
Instytut Medyczny Santa Familia
Lodz, , Poland
SP ZOZ Opolskie Centrum Onkologii - Oddzial Onkologii Klinicznej z Odcinkiem Dziennym
Opole, , Poland
Zachodniopomorskie Centrum Onkologii - Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych
Szczecin, , Poland
LUX MED Onkologia Sp. z o.o., Szpital Szamocka - Oddzial Onkologii Klinicznej/Chemioterapii
Warsaw, , Poland
Narodowy Instytut Onkologii im. Marii SkÅ'odowskiej-Curie â€" PaÅ"stwowy Instytut Badawczy - Klinika Nowotworow Piersi i Chirurg
Warsaw, , Poland
Centro Hospitalar e Universitário de Coimbra
Coimbra, , Portugal
Instituto Portugues de Oncologia de Lisboa Francisco Gentil - Oncologia Medica
Lisbon, , Portugal
Hospital da Luz de Lisboa - Learning Health
Lisbon, , Portugal
H. de Santa Maria. Centro Hospitalar Lisboa Norte - Oncologia
Lisbon, , Portugal
Hospital CUF Descobertas
Lisbon, , Portugal
Centro Hospitalar Universitario do Porto - H. Santo Antonio
Porto, , Portugal
Centrul de Oncologie Sf Nectarie - Medical Oncology
Baia Mare, , Romania
Oncopremium Team - Medical Oncology
Baia Mare, , Romania
Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca
Bucharest, , Romania
Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti
Cluj-Napoca, , Romania
Onco Clinic Consult
Craiova, , Romania
Radiotherapy Center Cluj
Floreşti, , Romania
Centrul de Oncologie Euroclinic
Iași, , Romania
Institutul Regional de Oncologie Iasi - Medical Oncology
Iași, , Romania
National Cancer Center - Breast Cancer
Goyang, , South Korea
Gachon University Gil Medical Center - Oncology
Incheon, , South Korea
CHA Bundang Medical Center - Oncology
Seongnam-si, , South Korea
Korea University Anam Hospital - Gastroenterological Surgery
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Yonsei University Health System, Severance hospital
Seoul, , South Korea
Asan Medical Center - Oncology
Seoul, , South Korea
Gangnam Severance Hospital
Seoul, , South Korea
Samsung Medical Center - Hematology & Oncology
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital - Hematology and Oncology
Seoul, , South Korea
Ajou University Hospital - Hematology/Oncology
Suwon, , South Korea
Ulsan University Hospital
Ulsan, , South Korea
Complexo Hospitalario Universitario A Coruña
A Coruña, , Spain
Hospital Universitario de Badajoz
Badajoz, , Spain
Hospital Del Mar
Barcelona, , Spain
Hospital Clinic De Barcelona
Barcelona, , Spain
Caceres Hospital Complex - San Pedro de Alcantara General Hospital
Cáceres, , Spain
Hospital Clínico Universitario Virgen De La Arrixaca
El Palmar, , Spain
Institut Catala D'oncologia
L'Hospitalet de Llobregat, , Spain
H.U Arnau De Vilanova Lleida
Lleida, , Spain
Hospital Beata Maria Ana de Jesus
Madrid, , Spain
Hospital Universitario Ramon y Cajal - Oncología Médica
Madrid, , Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, , Spain
Complejo Hospitalario Universitario De Santiago
Santiago de Compostela, , Spain
Fundacion Instituto Valenciano de Oncologia
Valencia, , Spain
Changhua Christian Medical Foundation - Changhua Christian Hospital - Neurology
Changhua, , Taiwan
National Taiwan University Hospital - Yunlin Branch - Oncology
Douliu, , Taiwan
Kaohsiung Medical University - Chung-Ho Memorial Hospital - Breast Surgery
Kaohsiung City, , Taiwan
China Medical University Hospital - Breast Surgery
Taichung, , Taiwan
Taichung Veterans General Hospital - General Surgery
Taichung, , Taiwan
National Cheng Kung University Hospital - Gynecology/Obstetrics
Tainan, , Taiwan
Chi Mei Medical Center - YongKang - Oncology and Hematology
Tainan, , Taiwan
National Taiwan University Hospital - Oncology
Taipei, , Taiwan
Taipei Medical University - Shuang Ho Hospital Ministry of Health and Welfare - Nephrology
Taipei, , Taiwan
Taipei Veterans General Hospital - Hematology
Taipei, , Taiwan
Taipei Municipal Wanfang Hospital - Managed by Taipei Medical University - Hematology and Oncology
Taipei, , Taiwan
King Chulalongkorn Memorial Hospital [Medical Oncology]
Bangkok, , Thailand
Rajavithi Hospital
Bangkok, , Thailand
Siriraj Hospital - Medical Oncology
Bangkok, , Thailand
Prince of Songkla University - Internal Medicine
Hat Yai, , Thailand
Banphaeo General Hospital
Samut Sakhon, , Thailand
Adana Baskent Practice and Research Hospital - Oncology
Adana, , Turkey (Türkiye)
Gulhane Training and Research Hospital - Medical Oncology
Ankara, , Turkey (Türkiye)
Hacettepe University Medical Faculty - Hematology
Ankara, , Turkey (Türkiye)
Dr Abdurrahman Yurtaslan Training and Research Hospital - Medical Oncology
Ankara, , Turkey (Türkiye)
Memorial Ankara Hastanesi
Ankara, , Turkey (Türkiye)
Ankara University Medical Faculty - Oncology
Ankara, , Turkey (Türkiye)
Dicle University Medical Faculty Hospital Medical Oncology
Diyarbakır, , Turkey (Türkiye)
Trakya University Medical Faculty - Oncology
Edirne, , Turkey (Türkiye)
Medical Park Hastaneler Grubu - I.A.U. VM Medical Park Florya
Istanbul, , Turkey (Türkiye)
Medipol Mega Hospital - Medical Oncology
Istanbul, , Turkey (Türkiye)
Istanbul Goztepe Prof. Dr. Suleyman Yalcin City Hospital - Medical Oncology
Istanbul, , Turkey (Türkiye)
Kocaeli Uni Egt ve Uyg Hast
İzmit, , Turkey (Türkiye)
Necmettin Erbakan University Meram Medical Faculty - Oncology
Konya, , Turkey (Türkiye)
VM Medical Park Mersin Hastanesi
Mezitli, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CELC-G-302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.